Therapeutic silencing of KRAS using systemically delivered siRNAs.
about
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentRAS isoforms and mutations in cancer at a glanceTP53 loss creates therapeutic vulnerability in colorectal cancer.KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines.Targeted polymeric nanoparticles for cancer gene therapy.Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts.
P2860
Q26751520-ED82719D-011E-417F-9550-79D5C15FA7F4Q28070394-64052F9F-9726-4411-847A-E827E098EEFEQ34473071-1CAEBD49-8240-4F9C-B130-C02552691A30Q35597456-421149F7-8D8F-4F22-A271-9D34BD535C5BQ36416427-A99F9104-B2BC-4DD1-97FE-169DCD0C2CAFQ37673912-5B13142A-6520-4CC4-A553-37B873F57C95Q38718304-B6BD7F73-246B-4F97-9F07-F2153226FC00Q38891257-60431600-E7F9-4713-BFE6-C6D811EB87D5Q39163561-B7AACEC4-5BD7-49F8-9FF5-6E68CD2A20ACQ47101598-CA09F846-251B-49FE-A144-3E3D47D9A87DQ50134163-28509C2A-DDE6-4C7C-95F6-7775DA6CF818Q52690264-57283FDF-D198-49F1-A46D-F2C5734052BE
P2860
Therapeutic silencing of KRAS using systemically delivered siRNAs.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Therapeutic silencing of KRAS using systemically delivered siRNAs.
@ast
Therapeutic silencing of KRAS using systemically delivered siRNAs.
@en
type
label
Therapeutic silencing of KRAS using systemically delivered siRNAs.
@ast
Therapeutic silencing of KRAS using systemically delivered siRNAs.
@en
prefLabel
Therapeutic silencing of KRAS using systemically delivered siRNAs.
@ast
Therapeutic silencing of KRAS using systemically delivered siRNAs.
@en
P2093
P2860
P50
P1476
Therapeutic silencing of KRAS using systemically delivered siRNAs.
@en
P2093
Anil K Sood
Anshumaan Maharaj
Behrouz Zand
Chad V Pecot
Gabriel Lopez-Berestein
Heather J Dalton
Justyna Filant
Lee M Ellis
Maria Pia Morelli
Salma Azam
P2860
P304
P356
10.1158/1535-7163.MCT-14-0074
P577
2014-10-03T00:00:00Z